Abstract
Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.
| Original language | English |
|---|---|
| Pages (from-to) | 1237-1244 |
| Number of pages | 8 |
| Journal | Bone Marrow Transplantation |
| Volume | 54 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. / Mussetti, Alberto; Martinetti, Nicolò; Cieri, Nicoletta; Pennisi, Martina; Dodero, Anna; Corradini, Paolo.
In: Bone Marrow Transplantation, Vol. 54, No. 8, 01.08.2019, p. 1237-1244.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas
AU - Mussetti, Alberto
AU - Martinetti, Nicolò
AU - Cieri, Nicoletta
AU - Pennisi, Martina
AU - Dodero, Anna
AU - Corradini, Paolo
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.
AB - Relapsed/refractory Peripheral T-cell Lymphomas are characterized by a poor prognosis, especially for patients who are not candidates for allogeneic hematopoietic stem-cell transplantation. We conducted a retrospective analysis on 73 consecutive patients affected by relapsed/refractory T-Cell lymphomas who were considered eligible for allogeneic transplant. All patients were referred at our center from 2001 to 2017. With a median follow-up of 40 months (range 9–192 months), 4-year second-line failure-free survival and overall survival were 14% (CI95%:7–24) and 34% (CI95%:22–46). Extranodal disease at relapse (HR 2.25, CI95%: 1.11–4.56, p = 0.02) and first-line failure-free survival < 12 months (HR 3.37, CI95%: 1.67–6.88, p < 0.01) had a negative prognostic impact on survival. Only 45 out of 73 patients (62%) received allogeneic transplant. For the 28 (38%) patients who did not proceed to transplant, disease progression was the main reason for ineligibility. Median survival from time of transplant was 31 months (range 4–185 months). A first-line failure-free survival < 12 months had a negative prognostic impact also for allografted patients (2-year survival 45% vs 73%, p = 0.03) identifying a very high-risk population which requires novel treatments pre and post-transplant to obtain a long-term disease control.
UR - http://www.scopus.com/inward/record.url?scp=85058190702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058190702&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0417-9
DO - 10.1038/s41409-018-0417-9
M3 - Article
C2 - 30531956
AN - SCOPUS:85058190702
VL - 54
SP - 1237
EP - 1244
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 8
ER -